ArticleJournal of neuroinflammation2026
β-oxidation-mediated differentiation of effector CD4
Article in Journal of neuroinflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Neuropsychiatric disorders in pulmonary fibrosis: from brain network alterations to inflammatory mechanisms and therapeutic implications.Journal of neuroinflammation · 2026Review
- Intravascular immune cell labeling as a critical methodological tool for characterizing CD4Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Although the lung-brain axis has emerged as a potential regulator of central nervous system (CNS) autoimmunity, the cellular and molecular mechanisms by which the lung microenvironment influences pathogenesis of multiple sclerosis (MS) remain unclear. Here, using experimental autoimmune encephalomyelitis (EAE), a murine model of MS, we found a marked expansion of effector CD4⁺ T cells in the lungs of EAE mice. The EAE lung microenvironment promoted metabolic reprogramming in CD4⁺ T cells, characterized by enhanced fatty acid uptake and upregulation of carnitine transporters. Metabolomic profiling further demonstrated enrichment of carnitine-related metabolites in the EAE lungs, with a strong correlation between metabolic profiles in the lungs and brains, suggesting coordinated metabolic remodeling along the lung-brain axis. Mechanistically, the EAE lung microenvironment significantly enhanced effector CD4⁺ T cell differentiation in vitro through a β-oxidation-dependent pathway. Importantly, pharmacological inhibition of β-oxidation in the lungs significantly attenuated EAE severity, reduced CD4⁺ T cell infiltration into the CNS, and impaired effector CD4⁺ T cell differentiation in the lungs. Collectively, these findings demonstrate that β-oxidation-mediated differentiation of effector CD4⁺ T cells in the lung exacerbates neuroinflammation, highlighting the lung-brain axis as a potential therapeutic target for MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.